Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/IRCT20150628022956N7
IRCT20150628022956N7CompletedPhase 2

Study of the effect of Silimarin on the reduction of liver complications of fingolimod in patients with Relapsing-Remitting Multiple Sclerosis (RRMS)

Research Council of Hamedan University of Medical Sciences0 sites48 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 2
Status
Completed
Sponsor
Enrollment
48
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
no limit to no limit (—)
Sex
All

Inclusion Criteria

  • •Patients who have had at least 3 weeks of onset of corticosteroid attack and received corticosteroids with liver enzymes following corticosteroid therapy.
  • •New Patients Receive Fingolimod
  • •Patients who are taking interferon and Glatiramer are advised to take the Fingolimod, provided they have no liver problem.
  • •Expanded Disability Status Scale below three.

Exclusion Criteria

  • •Pregnant and lactating women
  • •Patients who are allergic to Silymarin
  • •Patients with previous history of tuberculosis, HIV, hepatitis and liver problems.

Investigators

Sponsor
Research Council of Hamedan University of Medical Sciences

Similar Trials

Recruiting
Not Applicable
Investigation the effect of herbal supplement on lead concentratiolead poisoning.Abnormal lead level in bloodR78.71
IRCT20171122037584N1Hamedan University of Medical Sciences60
Not yet recruiting
Phase 3
Effect of silymarin in the treatment of patients with depressio
IRCT20160804029191N4Mashhad University of Medical Sciences80
Active, not recruiting
Phase 1
A dose-finding clinical study investigating the effects of different doses of silymarin compared to placebo on elevated liver enzymes due to drug-induced liver enzyme elevation.
EUCTR2020-004645-36-DEFraunhofer Gesellschaft for its Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP)156
Recruiting
Phase 3
Investigating the effects of Silymarin in the treatment of neonatal jaundice
IRCT20211122053144N1Mashhad University of Medical Sciences60
Recruiting
Phase 3
Evaluating the effectiveness of Silymarin on the prevention of gentamicin nephrotoxicityGentamicin-induced renal toxicity in hospitalized patients.Other bacterial diseasesA30-A49
IRCT20161010030246N3Shiraz University of Medical Sciences60